Collectively, in mice with established atherosclerosis, these results indicate that class IIa HDAC inhibition by systemic MC1568 administration leads to reduced EndMT and favorable changes in atherosclerotic plaque morphology. This evidence concerns the gene HDAC9 and atherosclerosis.